Literature DB >> 1089714

Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens.

R Champlin, R L Hunter.   

Abstract

Hen egg albumin (HEA), heavily conjugated with dodecanoic acid (D-HEA), stimulated sustained delayed type hypersensitivity (DTH) specific for HEA without detectable antibody formation in guinea pigs. An oil-in-water emulsion containing purified BCG cell walls attached to the oil drops was found to be a very effective adjuvant for enhancing DTH to D-HEA, but not to HEA. Animals immunized with D-HEA in the BCG cell wall emulsion produced skin test reactions 2.4 cm in diameter when challenged with HEA 21 days after a single immunization. Control animals immunized with D-HEA in saline produced skin reactions 1 cm in diameter to similar challenge. Neither group of animals produced detectable antibody to HEA-OR D-HEAmThe emulsion had no adjuvant effect if the BCG cell walls were suspended in the aqueous phase and not attached to the oil droplets. Dodecanoic acid conjugated Salmonella typhi organisms could be used in place of the BCG cell walls to produce effective adjuvant preparations. Fruend's complete adjuvant and other water-in-oil emulsions, however, were found to be ineffective adjuvants for enhancing the degree of DTH produced by D-HEA. Experiments with autoradiography demonstrated that effective adjuvant preparations promote the localization and retention of both 125-I-labeled D-HEA and 125-I-labeled BCG cell walls in the paracortical area of lymph nodes where they are in close proximity to many T-type lymphocytes which proliferate in the induction of DTH.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1089714

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Induction of delayed-type hypersensitivity with BCG-associated proteins.

Authors:  E D Crum; D D McGregor
Journal:  Immunology       Date:  1976-04       Impact factor: 7.397

Review 2.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

3.  Cutaneous granulomatous response to BCG cell walls with reference to cancer immunotherapy.

Authors:  D L Granger; W Brehmer; W Brehmer; K Yamamoto; E Ribi
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

4.  Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes.

Authors:  M A O'Donnell; A Aldovini; R B Duda; H Yang; A Szilvasi; R A Young; W C DeWolf
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

5.  Chemical modification and immunogenicity of membrane fractions from mouse tumour cells.

Authors:  H J Staab; F A Anderer
Journal:  Br J Cancer       Date:  1978-10       Impact factor: 7.640

Review 6.  Targeting TLR2 for vaccine development.

Authors:  Afonso P Basto; Alexandre Leitão
Journal:  J Immunol Res       Date:  2014-06-26       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.